title: Levobupivacaine 0.2% or 0.125% for continuous sciatic nerve block: a prospective, randomized, double-blind comparison with 0.2% ropivacaine.
abstract: In 60 patients receiving elective hallux valgus repair, we compared the efficacy of continuous popliteal sciatic nerve block produced with 0.2% ropivacaine (n = 20), 0.2% levobupivacaine (n = 20), or 0.125% levobupivacaine (n = 20) infused with a patient-controlled system starting 3 h after a 30-mL bolus of the 0.5% concentration of the study drug and for 48 h (baseline infusion rate, 6 mL/h; incremental dose, 2 mL; lockout time, 15 min; maximum incremental doses per hour, 3). No differences were reported in the intraoperative efficacy of the nerve block. The degree of pain was similar in the three groups throughout the study period, both at rest and during motion. Total consumption of local anesthetic solution during the first 24 h was 148 mL (range, 144-228 mL) with 0.2% ropivacaine, 150 mL (range, 144-200 mL) with 0.2% levobupivacaine, and 148 mL (range, 144-164 mL) with 0.125% levobupivacaine (P = 0.59). The volume of local anesthetic consumed during the second postoperative day was 150 mL (range, 144-164 mL) with 0.2% ropivacaine, 154 mL (range, 144-176 mL) with 0.2% levobupivacaine, and 151 mL (range, 144-216 mL) with 0.125% levobupivacaine (P = 0.14). A smaller proportion of patients receiving 0.2% levobupivacaine showed complete recovery of foot motor function as compared with 0.2% ropivacaine and 0.125% levobupivacaine, both at 24 h (35% vs 85% and 95%; P = 0.0005) and at 48 h (60% vs 100% and 100%; P = 0.001). We conclude that sciatic infusion with both 0.125% and 0.2% levobupivacaine provides adequate postoperative analgesia after hallux valgus repair, clinically similar to that provided by 0.2% ropivacaine; however, the 0.125% concentration is preferred if early mobilization of the operated foot is required.
authors.affiliation: Departments of *Anesthesiology and †Orthopedic Surgery, Vita-Salute University of Milano, Instituto di Ricovero e Cura a Carattere Scientifico San Raffaele Hospital, Milan, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Casati
authors.forename: Federico
authors.initials: F
authors.lastname: Vinciguerra
authors.forename: Gianluca
authors.initials: G
authors.lastname: Cappelleri
authors.forename: Giorgio
authors.initials: G
authors.lastname: Aldegheri
authors.forename: Crispino
authors.initials: C
authors.lastname: Grispigni
authors.forename: Marta
authors.initials: M
authors.lastname: Putzu
authors.forename: Paola
authors.initials: P
authors.lastname: Rivoltini
mesh_terms: D000328:Adult; D000368:Aged; D000577:Amides / Q000494:pharmacology*; D002045:Bupivacaine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D000077554:Levobupivacaine; D008297:Male; D008875:Middle Aged; D009407:Nerve Block; D010149:Postoperative Pain / Q000188:drug therapy*; D011446:Prospective Studies; D000077212:Ropivacaine; D012584:Sciatic Nerve
chemical_list: D000577:Amides; D000077212:Ropivacaine; D000077554:Levobupivacaine; D002045:Bupivacaine